Scarica l'app Stockscreener
8.08
9.82%
-0.88
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ETNB Giù?
Forum
Previsione
Precedente Chiudi:
$8.96
Aprire:
$8.94
Volume 24 ore:
1.92M
Relative Volume:
0.85
Capitalizzazione di mercato:
$1.31B
Reddito:
-
Utile/perdita netta:
$-174.61M
Rapporto P/E:
-4.1015
EPS:
-1.97
Flusso di cassa netto:
$-165.54M
1 W Prestazione:
-5.16%
1M Prestazione:
-13.30%
6M Prestazione:
+11.37%
1 anno Prestazione:
-30.58%
Intervallo 1D:
$7.90
$8.94
Intervallo di 1 settimana:
$7.66
$9.318
Portata 52W:
$5.9857
$11.84
89 Bio Inc Stock (ETNB) Company Profile
Nome
89 Bio Inc
Settore
Industria
Telefono
(415) 432-9270
Indirizzo
142 SANSOME STREET, SAN FRANCISCO, CA
Confronta ETNB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ETNB
89 Bio Inc
|
8.08 | 1.31B | 0 | -174.61M | -165.54M | -1.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
89 Bio Inc Stock (ETNB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-14 | Iniziato | Goldman | Neutral |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-04-22 | Ripresa | BofA Securities | Buy |
| 2024-01-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-10 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-08-28 | Iniziato | UBS | Buy |
| 2023-06-13 | Iniziato | Evercore ISI | Outperform |
| 2022-05-12 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2021-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-26 | Ripresa | Cantor Fitzgerald | Overweight |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-04-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-19 | Iniziato | Raymond James | Strong Buy |
| 2020-09-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-23 | Iniziato | BTIG Research | Buy |
| 2020-07-07 | Iniziato | Chardan Capital Markets | Buy |
| 2019-12-09 | Iniziato | BofA/Merrill | Neutral |
| 2019-12-09 | Iniziato | Oppenheimer | Outperform |
| 2019-12-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-12-09 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
89 Bio Inc Borsa (ETNB) Ultime notizie
Are 89bio Inc (NASDAQ: ETNB) Analysts Predicting A Spike? - Stocks Register
Victory Capital Management Inc. Acquires 1,437 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
PNC Financial Services Group Inc. Increases Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio (NASDAQ:ETNB) Given Sell (D-) Rating at Weiss Ratings - Defense World
89bio, Inc. (NASDAQ:ETNB) Stock Holdings Lifted by Bank of New York Mellon Corp - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $27.56 Average Target Price from Analysts - Defense World
89bio, Inc. (NASDAQ:ETNB) Shares Sold by Steward Partners Investment Advisory LLC - Defense World
89bio (NASDAQ:ETNB) Research Coverage Started at The Goldman Sachs Group - Defense World
Citigroup Initiates Coverage on 89bio (NASDAQ:ETNB) - Defense World
Goldman Sachs starts 89bio stock with neutral, $11 target By Investing.com - Investing.com Australia
Goldman Sachs Initiates Coverage of 89bio (ETNB) with Neutral Recommendation - Nasdaq
Goldman Sachs Initiates Coverage on 89bio With Neutral Rating, $11 Price Target -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Goldman Sachs starts 89bio stock with neutral, $11 target - Investing.com India
89bio initiated with a Neutral at Goldman Sachs - TipRanks
Commit To Buy 89bio At $7.50, Earn 25.1% Annualized Using Options - Nasdaq
Citigroup Initiates Coverage of 89bio (ETNB) with Buy Recommendation - Nasdaq
Citigroup Initiates 89bio Inc at Buy With $25 Price Target -March 13, 2025 at 07:13 am EDT - Marketscreener.com
89bio initiated with a Buy at Citi - TipRanks
Time nigh for I&I? Key data points ahead - BioWorld Online
89bio Inc (NASDAQ: ETNB) Is On The Fall - Stocks Register
89bio (NASDAQ:ETNB) Earns Sell (D-) Rating from Weiss Ratings - Defense World
Rhumbline Advisers Has $1.02 Million Stock Position in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio FY2025 EPS Forecast Increased by Cantor Fitzgerald - Defense World
Boston Pharma Plays Catch Up To Akero, 89bio In MASH - Citeline News & Insights
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
New York State Common Retirement Fund Has $128,000 Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
89bio to Participate in the Leerink Partners Global Healthcare Conference - The Manila Times
Can 89bio's Liver Disease Pipeline Impress Investors at Upcoming Leerink Conference? - StockTitan
Cantor maintains Overweight on 89bio stock, price target at $29 - Investing.com
Cantor maintains Overweight on 89bio stock, price target at $29 By Investing.com - Investing.com UK
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts 89bio stock price target to $21, maintains Buy - Investing.com
89bio’s (ETNB) “Buy” Rating Reiterated at HC Wainwright - Defense World
89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products - MSN
Decoding 89bio Inc (ETNB): A Strategic SWOT Insight - GuruFocus.com
89bio Inc. Advances Clinical Trials Amid Financial Losses - TipRanks
89bio (NASDAQ:ETNB) Stock Price Down 9.1%What's Next? - MarketBeat
89bio (NASDAQ:ETNB) Announces Earnings Results, Misses Estimates By $0.42 EPS - MarketBeat
Cantor Fitzgerald maintains 89bio stock with $29 target By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains 89bio stock with $29 target - Investing.com
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates - The Globe and Mail
89bio, Inc. SEC 10-K Report - TradingView
89bio Secures $727.5M War Chest While Advancing Critical Phase 3 Trials — What's Next for ETNB? - StockTitan
89bio (ETNB) Projected to Post Earnings on Thursday - Defense World
89bio, Inc. (NASDAQ:ETNB) Receives $31.43 Consensus PT from Brokerages - Defense World
Weiss Ratings Reaffirms "Sell (D-)" Rating for 89bio (NASDAQ:ETNB) - MarketBeat
Cell Sorting Market Size to Hit USD 601.89 Million by 2034 - BioSpace
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High? - MSN
89bio, Inc. (NASDAQ:ETNB) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Should You Buy 89BIO (ETNB) After Golden Cross? - Nasdaq
Weiss Ratings Reiterates Sell (D-) Rating for 89bio (NASDAQ:ETNB) - Defense World
89 Bio Inc Azioni (ETNB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
89 Bio Inc Azioni (ETNB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McWherter Charles | Director |
Jan 22 '25 |
Buy |
6.71 |
10,000 |
67,100 |
25,000 |
| McWherter Charles | Director |
Jan 21 '25 |
Buy |
6.55 |
5,000 |
32,750 |
15,000 |
| Le-Nguyen Quoc | See Remarks |
Jan 15 '25 |
Sale |
6.49 |
10,963 |
71,150 |
271,833 |
0.39%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):